Filing Flows › Cytosorbents (CTSO) › Q1 2025
Cytosorbents (CTSO) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 14, 2025
Cytosorbents (CTSO) reported revenue of $8.7M for the first quarter 2025 (Q1 2025), -3% from a year earlier and +34% from the quarter before. Operating margin was -44.6%, net loss $1.5M (16.9% of revenue).
Cytosorbents, Q1 2025: revenue $8.7M (-3% year over year), operating margin -44.6%, net loss $1.5M, operating cash flow −$3.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.7M | +34% | -3% |
| Operating profit | −$3.9M | — | — |
| Net earnings | −$1.5M | — | — |
| Operating cash flow | −$3.5M | — | — |
What changed
Revenue was $8.7M in Q1 2025, down 3% year over year and up 34% from the previous quarter.
Gross margin was 71.1%, down 5.3 points from a year earlier. Operating costs exceeded revenue by $3.9M, an operating margin of -44.6%. Operating expenses fell 12% while revenue fell 3%. The quarter ended with a net loss of $1.5M, narrower than the previous quarter's $7.6M loss. Non-operating items added $2.4M, -163% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$3.5M. Non-cash charges added back $369K of depreciation and amortization and $818K of share-based compensation. Working capital and other items used $3.2M. Capital expenditures of $2K exceeded it, leaving free cash flow of −$3.5M.
Questions
What was Cytosorbents' revenue in the first quarter 2025?
Cytosorbents (CTSO) reported revenue of $8.7M for the first quarter 2025 (Q1 2025), -3% from a year earlier and +34% from the quarter before.
Was Cytosorbents profitable in the first quarter 2025?
Operating loss was $3.9M (-44.6% of revenue) and net loss $1.5M.
Source: Cytosorbents 10-Q on SEC EDGAR.